BibTex format
@article{Goodwin:2022:10.1056/NEJMoa2206443,
author = {Goodwin, GM and Aaronson, ST and Alvarez, O and Arden, PC and Baker, A and Bennett, JC and Bird, C and Blom, RE and Brennan, C and Brusch, D and Burke, L and Campbell-Coker, K and Carhart-Harris, R and Cattell, J and Daniel, A and DeBattista, C and Dunlop, BW and Eisen, K and Feifel, D and Forbes, M and Haumann, HM and Hellerstein, DJ and Hoppe, AI and Husain, MI and Jelen, LA and Kamphuis, J and Kawasaki, J and Kelly, JR and Key, RE and Kishon, R and Knatz, Peck S and Knight, G and Koolen, MHB and Lean, M and Licht, RW and Maples-Keller, JL and Mars, J and Marwood, L and McElhiney, MC and Miller, TL and Mirow, A and Mistry, S and Mletzko-Crowe, T and Modlin, LN and Nielsen, RE and Nielson, EM and Offerhaus, SR and O'Keane, V and Páleníek, T and Printz, D and Rademaker, MC and van, Reemst A and Reinholdt, F and Repantis, D and Rucker, J and Rudow, S and Ruffell, S and Rush, AJ and Schoevers, RA and Seynaeve, M and Shao, S and Soares, JC and Somers, M and Stansfield, SC and Sterling, D },
doi = {10.1056/NEJMoa2206443},
journal = {N Engl J Med},
pages = {1637--1648},
title = {Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.},
url = {http://dx.doi.org/10.1056/NEJMoa2206443},
volume = {387},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression. METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression). Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits). RESULTS: A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group. The mean MADRS total score at baseline was 32 or 33 in each group. Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18). In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results. Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups. CONCLUSIONS: In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including compariso
AU - Goodwin,GM
AU - Aaronson,ST
AU - Alvarez,O
AU - Arden,PC
AU - Baker,A
AU - Bennett,JC
AU - Bird,C
AU - Blom,RE
AU - Brennan,C
AU - Brusch,D
AU - Burke,L
AU - Campbell-Coker,K
AU - Carhart-Harris,R
AU - Cattell,J
AU - Daniel,A
AU - DeBattista,C
AU - Dunlop,BW
AU - Eisen,K
AU - Feifel,D
AU - Forbes,M
AU - Haumann,HM
AU - Hellerstein,DJ
AU - Hoppe,AI
AU - Husain,MI
AU - Jelen,LA
AU - Kamphuis,J
AU - Kawasaki,J
AU - Kelly,JR
AU - Key,RE
AU - Kishon,R
AU - Knatz,Peck S
AU - Knight,G
AU - Koolen,MHB
AU - Lean,M
AU - Licht,RW
AU - Maples-Keller,JL
AU - Mars,J
AU - Marwood,L
AU - McElhiney,MC
AU - Miller,TL
AU - Mirow,A
AU - Mistry,S
AU - Mletzko-Crowe,T
AU - Modlin,LN
AU - Nielsen,RE
AU - Nielson,EM
AU - Offerhaus,SR
AU - O'Keane,V
AU - Páleníek,T
AU - Printz,D
AU - Rademaker,MC
AU - van,Reemst A
AU - Reinholdt,F
AU - Repantis,D
AU - Rucker,J
AU - Rudow,S
AU - Ruffell,S
AU - Rush,AJ
AU - Schoevers,RA
AU - Seynaeve,M
AU - Shao,S
AU - Soares,JC
AU - Somers,M
AU - Stansfield,SC
AU - Sterling,D
AU - Strockis,A
AU - Tsai,J
AU - Visser,L
AU - Wahba,M
AU - Williams,S
AU - Young,AH
AU - Ywema,P
AU - Zisook,S
AU - Malievskaia,E
DO - 10.1056/NEJMoa2206443
EP - 1648
PY - 2022///
SP - 1637
TI - Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
T2 - N Engl J Med
UR - http://dx.doi.org/10.1056/NEJMoa2206443
UR - https://www.ncbi.nlm.nih.gov/pubmed/36322843
VL - 387
ER -
